The goal of the Bone and Joint Decade is to improve the health related quality of life for people with musculoskeletal disorders throughout the world. Musculoskeletal disorders are the most common ...

10 Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA 11 Department of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA 12 ...

The development of articular manifestations in the course of chronic urticaria or in urticarial vasculitis has been widely reported. It is not completely clear, however, whether common pathogenetic ...

Correspondence to Dr Zachary Scott Wallace, Division of Rheumatology, Allergy, and Immunology and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General ...

Department of Immunology and Transfusion Medicine, Ullevaal University Hospital, Oslo, Norway Correspondence to: Dr J Kjeldsen-Kragh, Department of Immunology and Transfusion Medicine, Ullevaal ...

Objectives To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical ...

1 Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2 University of Maryland, Baltimore, Maryland, USA Correspondence to Dr Michelle Petri, Professor of Medicine, Johns Hopkins ...

41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...

Objective: To compare the clinical efficacy of methotrexate and tolerance to the drug in patients with rheumatoid arthritis who were switched from intramuscular to oral administration because of a ...

Background: Loss of articular cartilage is one of the major signs of osteoarthritis (OA). Aggrecan, the main proteoglycan component of the extracellular matrix of articular cartilage is cleaved by ...

Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...